Race, response to chemotherapy, and outcome within clinical breast cancer subtypes

J. R. Tichy(University of North Carolina at Chapel Hill), Lisa A. Carey(University of North Carolina at Chapel Hill), Carey K. Anders(Duke University), Katherine E. Reeder‐Hayes(University of North Carolina at Chapel Hill), Allison M. Deal(Memorial Sloan Kettering Cancer Center)
Breast Cancer Research and Treatment
March 26, 2015
10.1007/s10549-015-3350-2
Cited by 61

Related Papers

Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
|JAMA|2017|2.3k
The molecular portraits of breast tumors are conserved across microarray platforms
|BMC Genomics|2006|1.5k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k